本文選題：非肌層浸潤(rùn)性膀胱腫瘤 + 　； 參考：《中國(guó)老年學(xué)雜志》2015年10期

【摘要】：目的探討非肌層浸潤(rùn)性膀胱腫瘤術(shù)后復(fù)發(fā)和進(jìn)展評(píng)分對(duì)預(yù)測(cè)其患者預(yù)后的臨床價(jià)值。方法依據(jù)非肌層浸潤(rùn)性膀胱腫瘤術(shù)后復(fù)發(fā)和進(jìn)展危險(xiǎn)評(píng)分系統(tǒng)(EORTC)對(duì)2005年4月至2009年9月該院收治的131例非肌層浸潤(rùn)性膀胱腫瘤患者術(shù)后進(jìn)行評(píng)分,并計(jì)算各評(píng)分等級(jí)組術(shù)后患者的1、3、5年復(fù)發(fā)率和進(jìn)展率。結(jié)果依據(jù)復(fù)發(fā)評(píng)分計(jì)算后分為0分組、1~4分組、5~9分組和10~17分組,其中患者術(shù)后1、3、5年復(fù)發(fā)率與歐洲膀胱治療研究組織(EORTC)評(píng)分預(yù)測(cè)的參照復(fù)發(fā)比較無(wú)顯著差異(P0.05);依據(jù)進(jìn)展評(píng)分計(jì)算后分為0分組、2~6分組、7~13分組、14~23分組,其中患者術(shù)后1、3、5年進(jìn)展率與EORTC評(píng)分預(yù)測(cè)的進(jìn)展率比較無(wú)顯著差異(P0.05)。結(jié)論根據(jù)非肌層浸潤(rùn)性膀胱腫瘤患者術(shù)后評(píng)分實(shí)際情況將其分為不同評(píng)分等級(jí),對(duì)患者預(yù)測(cè)1~5年的預(yù)后具有重要的臨床意義,但目前有待多中心、大樣本臨床試驗(yàn)進(jìn)一步驗(yàn)證。
[Abstract]:Objective to evaluate the clinical value of non-myometrial invasive bladder tumor recurrence and progression score in predicting the prognosis. Methods 131 patients with non-myometrial invasive bladder tumor who were treated in our hospital from April 2005 to September 2009 were evaluated according to the risk of recurrence and progression of non-muscular invasive bladder tumor. The recurrence rate and progression rate of each grade group were calculated. Results according to the recurrence score, the patients were divided into 0, 1, 4, 5, 9, and 10, 17 groups, respectively. Among them, there was no significant difference between the recurrence rate of 3 and 5 years after operation and the reference recurrence predicted by the European bladder treatment Research Organization (EORTC) score (P 0.05), and the patients were divided into 0 group, 2 group, 7 group, 13 group and 14 23 group, according to the progress score, there was no significant difference between them. There was no significant difference in the rate of progression between 3 and 5 years after operation and that predicted by EORTC score (P 0.05). Conclusion according to the actual situation of non-myometrial invasive bladder tumor patients, they can be divided into different grades, which has important clinical significance in predicting the prognosis of patients for 1 ~ 5 years, but it needs to be further verified by multi-center and large sample clinical trials.
【作者單位】： 甘肅省人民醫(yī)院泌尿外科;
【分類號(hào)】：R737.14

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 遲慶龍;王艷波;王春喜;;水飛薊賓對(duì)人膀胱癌細(xì)胞系T24和5637的增殖抑制及凋亡誘導(dǎo)作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年02期

2 全翔鳳;姚莉;唐冬媛;伍琳凌;潘柳霖;吳秋蘭;;膀胱癌術(shù)后早期膀胱灌注化療的護(hù)理[J];當(dāng)代護(hù)士(中旬刊);2014年05期

3 容祖益;梁建波;李偉;;初次經(jīng)尿道膀胱腫瘤電切術(shù)后腫瘤殘留的多因素分析[J];廣西醫(yī)學(xué);2014年12期

4 許天源;朱照偉;鐘山;張小華;王先進(jìn);張敏光;沈周俊;;EORTC風(fēng)險(xiǎn)量表對(duì)非肌層浸潤(rùn)性膀胱癌術(shù)后即刻灌注化療預(yù)后判斷的研究[J];臨床泌尿外科雜志;2013年07期

5 梁勝杰;鄒青松;韓邦e，

本文編號(hào)：1980387